Reflexion Medical has raised $46 million to develop the first biology-guided radiotherapy system that offers targeted cancer treatment. Last fall, the Hayward, CA-based startup said it had created a prototype device that was ready to go into the clinic. This Series B infusion is earmarked for expanding the company's engineering, regulatory and commercial groups.
Back in February, tech giant Intel said that it would launch a new program under President Barack Obama's Precision Medicine Initiative (PMI) to improve data analytics for genomics research. Now, the company's general manager of Health & Life Sciences is moving camps and joining the National Institutes of Health to lead PMI research.
IBM will announce a pair of new Watson Health initiatives. One is with the American Cancer Society to apply the power of artificial intelligence to patient-oriented healthcare information, the other is an effort dubbed IBM Health Corps that aims to apply Watson's AI capabilities to better solve global health challenges.
Irish startup Advanced Surgical Concepts has nabbed an FDA nod for its tissue containment system for use with certain laparoscopic power morcellators. The regulatory go-ahead falls under the agency's de novo process that's reserved for low- to moderate-risk devices that are novel.
Work on human breast cancer cells and mice has helped researchers at the Johns Hopkins University explain how some cancer stem cells (CSCs) thrive when oxygen supply is limited. CSCs are a major source for chemotherapy resistance and tumors spreading, and this research highlights a potential pathway that may be blocked to prevent their proliferation.
Medical imaging deep learning startup Arterys has a major partnership with GE and a cardio product launch teed up as part of that for this fall. Now, it's lined up a more than $12 million Series A financing to help it transition into its next field: oncology. The San Francisco, CA-based startup had previously disclosed a smaller sum for that Series A of $7 million late last year.
Prostate cancer genomics company GenomeDx Biosciences has raised $25.4 million to back its prostate cancer genomic testing, according to a March 10 SEC filing. The financing disclosure comes just after the San Diego, CA-based startup launched its latest prostate cancer test, Decipher Biopsy, earlier this month. GenomeDx already markets Decipher Post-Op, making the new test its second on the market.
MIT researchers have found that amino acids contribute more to the building blocks of new cells than glucose does. Since the bulk of the raw cellular mass was traditionally thought to have come from glucose, this new research may have implications in how we think of the molecules that make up cells--including how we can use this information to target cancer growth.
Pfizer's CDK inhibitor Ibrance made a splash last year when it won a speedy FDA nod for breast cancer, with competitors from Novartis and Eli Lilly in pursuit. But this class of drugs may have applications beyond breast cancer: researchers from Mount Sinai's Icahn School of Medicine have identified a CDK4/ARK5 inhibitor as a potential new weapon against the fatal blood cancer, multiple myeloma.
Usefully integrating genomic data into actual treatment of patients remains a huge stumbling block in what's expected to be the age of precision medicine. That's particularly true in cancer treatment, where a particular patient's tumors can each have their own complex genomics that relate to the treatment strategy as a whole.